Pharmacy Department, Maudsley Hospital, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, SE5 8AZ, UK.
CNS Drugs. 2020 Aug;34(8):841-852. doi: 10.1007/s40263-020-00735-3.
Antipsychotic long-acting injections improve relapse prevention in psychotic disorders. Three new risperidone formulations have been developed that offer advantages over currently available risperidone-based long-acting injections. Risperidone ISM is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. RBP-7000 is a monthly subcutaneous injection not requiring loading or oral supplementation. BB0817 is a 6-monthly implant of risperidone injected subcutaneously. All three preparations have been shown to be effective and well tolerated in clinical trials. A fourth formulation (TV-46000), which can be given subcutaneously every 1 or 2 months, has recently begun trials.
抗精神病长效注射剂可改善精神障碍的复发预防。目前已经开发出三种新型利培酮制剂，它们比现有的利培酮长效注射剂具有优势。利培酮 ISM 是一种每月一次的肌肉注射剂，不需要负荷剂量或同时口服利培酮。RBP-7000 是一种每月一次的皮下注射剂，不需要负荷剂量或口服补充。BB0817 是一种每 6 个月皮下注射一次的利培酮植入物。所有三种制剂在临床试验中均显示有效且耐受性良好。最近开始试验的第四种制剂（TV-46000）可每 1 或 2 个月皮下给药一次。
